A CME Dinner Program Series

Biosimilar Insulins Are Coming:

The Top 10 Things You Should Know and Other New and Novel Insulins on the Therapeutic Horizon

The Med-IQ/Taking Control Of Your Diabetes New and Emerging Insulin Continuing Medical Education evening series will be offered in eight different cities during the 2015 year.

The goal of this ‘New and Emerging Insulins’ continuing medical education activity is two fold. The first is to prepare providers for the future availability of biosimilar insulins, as many branded, long- and rapid-acting insulin analogs lose patent protection. The second is to provide a clinical update regarding the newer insulins recently approved and on the horizon for the treatment of both type 1 and type 2 diabetes. This will be accomplished by providing both a foundation of knowledge and a contextual framework, enabling the learner to become more familiar with – and better understand – biosimilar insulins’ safety, efficacy, cost-effectiveness, place in the diabetes treatment algorithm, and their ultimate impact on patient management. In addition, the clinical features of these new insulins will be reviewed and how to use them in clinical practice will be illustrated.

2015 New and Emerging Insulin Dinner Series

  • April 1, 2015
    Kansas City - The Westin Kansas City at Crown Point
  • July 14, 2015
    San Diego, CA - La Jolla Hyatt
  • August 20, 2015
    Omaha, NE - Sheraton Omaha Hotel
  • September 1, 2015
    Phoenix, AZ - Arizona Grand Resort
  • December 2, 2015
    Anchorage, AK - Venue TBA
  • January 13, 2016
    Sacramento, CA - Sheraton Grand Sacramento Hotel
  • February 18, 2016
    Memphis, TN - The Peabody Memphis
  • February 22, 2016
    Honolulu, HI - Halekulani

Acknowledgment of Commercial Support

  • This activity is supported by an educational grant from sanofi-aventis U.S.